North Dakota State Investment Board Invests $2.12 Million in Cencora, Inc. $COR

North Dakota State Investment Board bought a new position in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 6,269 shares of the company’s stock, valued at approximately $2,117,000.

Several other institutional investors also recently modified their holdings of COR. Oakworth Capital Inc. acquired a new position in shares of Cencora during the 4th quarter worth about $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora during the 4th quarter worth about $27,000. Archer Investment Corp grew its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the period. IAG Wealth Partners LLC acquired a new position in shares of Cencora during the 3rd quarter worth about $30,000. Finally, Cloud Capital Management LLC acquired a new position in shares of Cencora during the 3rd quarter worth about $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of COR opened at $262.15 on Tuesday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a 50 day simple moving average of $312.71 and a 200 day simple moving average of $338.72. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The firm has a market capitalization of $51.00 billion, a PE ratio of 20.10, a P/E/G ratio of 1.19 and a beta of 0.64.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the prior year, the firm posted $4.42 earnings per share. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.76 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Analyst Ratings Changes

COR has been the subject of several analyst reports. Barclays boosted their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. JPMorgan Chase & Co. boosted their price objective on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Robert W. Baird decreased their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a research report on Friday, May 8th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.